AlzeCure Pharma has entered a collaboration and out-licensing agreement with Eli Lilly, granting Lilly global rights to its Alzheimer's drug candidate ACD680, in a deal that could exceed $1 billion in total value.

What is ACD680?

ACD680 is a gamma-secretase modulator (GSM) being developed within AlzeCure's Alzstatin platform, designed to reduce the production of amyloid-beta 42 (Aβ42), the harmful protein that forms the building blocks of amyloid plaques found in the brains of Alzheimer's patients.² Unlike therapies that target existing plaques, ACD680 acts upstream by modulating the enzyme responsible for producing Aβ42 in the first place.

The drug is also designed to increase the production of shorter, benign amyloid proteins, Aβ37 and Aβ38, which may further reduce the aggregation of Aβ42 and limit plaque accumulation.²

"Gamma-secretase modulators, which we have developed within the Alzstatin platform, are small-molecule drugs where the mechanism has a strong genetic link to the disease," said Johan Sandin, chief scientific officer at AlzeCure Pharma.

What are the details of the deal?

Under the terms of the agreement, AlzeCure is set to receive a $10 million upfront payment, along with development and commercial milestone payments and tiered mid-single digit royalties on sales.¹ The total deal value, excluding royalties, has the potential to exceed $1 billion.

The transaction is subject to customary closing conditions, including approval by Swedish authorities under foreign direct investment regulations.

Why is this approach potentially significant?

GSMs represent a distinct class of Alzheimer's intervention compared to the antibody therapies that have dominated recent development and approval activity. ACD680 is an oral small molecule, meaning it can be taken in tablet form, readily crosses the blood-brain barrier, and can be produced at lower cost than biologic alternatives.²

AlzeCure positions the drug as a potential preventive and disease-modifying therapy for early-stage Alzheimer's, an area of growing clinical and commercial focus as the field shifts toward earlier intervention before significant neurodegeneration has occurred.

"With Alzstatin, we want to offer a preventive and disease-modifying treatment against Alzheimer's in the form of an oral therapy, which is non-invasive for patients," said Gunnar Nordvall, project leader and director of medicinal chemistry at AlzeCure. He also noted that ACD680 derives from a new series of molecules expected to offer patent advantages, with a significantly longer patent period than earlier candidates.²

"The Alzstatin compounds are hoped to be used to counteract re-accumulation of harmful amyloid in the brain," said AlzeCure CEO Martin Jönsson. "In the long term, these compounds may also serve as a preventive treatment to prevent the development of Alzheimer's disease."

For Lilly, the agreement adds an early-stage oral amyloid-lowering asset to a portfolio already active in Alzheimer's therapeutics. For AlzeCure, the deal validates its Alzstatin platform and provides capital to advance its broader CNS pipeline, which spans Alzheimer's disease and pain.¹

The company has framed the licensing agreement as evidence of its strategy to develop multiple drug candidates in parallel and capitalize on what it describes as growing commercial interest in the Alzheimer's field.

Sources

1. AlzeCure Pharma Enters Into A Collaboration And Out-Licensing Agreement With Lilly For Alzheimer's Project AlzeCure Pharma June 9, 2026https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/alzecure-pharma-enters-into-a-collaboration-and-out-licensing-agreeme-1174386
2. AlzeCure Selects CD and Enters Next Development Phase with Alzstatin ACD680 Against Alzheimer’s AlzeCure Pharma January 11, 2023 https://www.alzecurepharma.se/en/alzecure-selects-cd-and-enters-next-development-phase-with-alzstatin-acd680-against-alzheimers/